FDA tarlatamab coverage for business development, investment, and market access teams
The FDA has approved Amgen's bispecific antibody, providing a new treatment option for patients battling metastatic colorectal cancer.
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
